U.S. markets open in 1 hour 38 minutes

CV Sciences, Inc. (CVSI)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.4665-0.0135 (-2.81%)
At close: 3:51PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4800
Open0.4900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4600 - 0.4900
52 Week Range0.2500 - 2.1400
Volume210,305
Avg. Volume354,241
Market Cap46.597M
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-0.1900
Earnings DateMay 08, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.93
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • CV Sciences, Inc. to Announce Third Quarter 2020 Results on November 5, 2020
    GlobeNewswire

    CV Sciences, Inc. to Announce Third Quarter 2020 Results on November 5, 2020

    SAN DIEGO, Oct. 23, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the third quarter ended September 30, 2020, after the stock market closes on Thursday, November 5, 2020. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day. The webcast of the conference call will be available on the Investor Relations section of the Company's website at https://ir.cvsciences.com/news-events and at http://public.viavid.com/index.php?id=142188. The webcast will be archived for approximately 30 days.Investors interested in participating in the live call can also dial (800) 909-4985 from the U.S. or international callers can dial (212) 231-2921. Please dial the conference telephone number 15 minutes prior to the start time due to increased demand for conference calls.A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, November 12, 2020, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 21971382.About CV Sciences, Inc.CV Sciences, Inc. (CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics. The Company’s flagship brand of PlusCBD™ Oil products are sold at more than 5,700 retail locations throughout the U.S. and it is the top-selling brand of hemp-derived CBD in the natural product retail channel, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences’ state-of-the-art facility follows all guidelines for Good Manufacturing Practices (GMP) and our hemp extracts are processed, produced, and tested throughout the manufacturing process to confirm the cannabinoid content meets strict company standards. With a commitment to science, PlusCBD™ Oil’s benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. PlusCBD™ Oil was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.FORWARD-LOOKING DISCLAIMERThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.CONTACT INFORMATION:Investor Contact: ICR Scott Van Winkle 617-956-6736 CVSciences@icrinc.comMedia Contact: ICR Cory Ziskind 646-277-1232 cory.ziskind@icrinc.com

  • CV Sciences, Inc. Announces PlusCBD™ Brand Refresh and New Product Launches
    GlobeNewswire

    CV Sciences, Inc. Announces PlusCBD™ Brand Refresh and New Product Launches

    PlusCBD™ refresh reflects the brand’s core mission to improve quality of life through nature and science PlusCBD Formulas PlusCBD FormulasSAN DIEGO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced a comprehensive refresh of its top selling, flagship PlusCBD™ branded product line and the launch of 30+ new PlusCBD™ products over the next 45 days. The new PlusCBD™ brand is a refinement and modernization that includes new packaging with a contemporary color palette and a post-modern aesthetic to relay each product’s value proposition across the product offering. The 30+ new product launch includes eight new, innovative products featuring extra strength gummies and maximum strength softgels. All new PlusCBD™ branded products are available on our website at www.cvsciences.com.The refreshed PlusCBD™ packaging features our new, prominently displayed CV Sciences logo, transparent QR code labeling linked to lab reports to assure customers of the unrivaled quality, and the milligrams of CBD per serving on the label.The PlusCBD™ brand mission statement is now featured on the packaging: “Modern life is challenging. Our physical, mental and emotional health is constantly being tested. CV Sciences provides research based solutions for the well-being of the planet. Our mission is to improve quality of life through nature and science – and the results speak for themselves. This is health transformed.”“The CV Sciences team is thrilled to introduce our refreshed PlusCBD™ products that will leverage our brand equity as the safest and most trusted CBD product offering available, all designed to resonate with our existing customers while attracting new consumers,” said Joseph Dowling, Chief Executive Officer. “We conducted extensive market research to create a fresh new look with strong value messaging that will drive long-term brand affinity with a broad consumer audience focused on health and wellness. Our updated brand and products position CV Sciences for continued growth and industry leadership in the hemp derived CBD category.”The top selling CBD brand on the market, PlusCBD™ showcases the synergistic benefits of full spectrum hemp extract, which constitutes over 500 compounds, including CBD, cannabinoids, terpenes, and essential fatty acids. PlusCBD™ is sourced from sustainable, non-GMO U.S. hemp, grown on small farms in Kentucky, and EU certified hemp cultivated by Dutch farmers with decades of experience.As the first company to achieve Generally Recognized as Safe (GRAS) status for hemp derived CBD, CV Sciences offers the highest quality products by: * Sourcing hemp extracts from superior quality U.S. and EU grown agricultural hemp * Maintaining two third party Good Manufacturing Practice certifications (U.S. Hemp Authority and Eurofins) * Batch testing in-house and by 3rd party labs throughout the process to preserve product integrity * Investing in hemp derived CBD research, including CV Sciences published pre-clinical safety studies, multiple published PlusCBD case studies, a randomized clinical trial using Plus CBD, and published post market safety assessment of CV Sciences products.About CV Sciences, Inc.CV, or Curriculum Vitae, is Latin for “course of life”, and science is the pursuit of truth. CV Sciences: our name is our mission -- improving quality of life through nature and science.CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based dietary supplements and CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics. The Company’s PlusCBD™ products are sold at more than 6,300 retail locations throughout the U.S. and it is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry.  CV Sciences follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s products are processed, produced, and tested throughout the manufacturing process to confirm strict compliance with company standards and specifications.  With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov.  PlusCBD™ was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California.  Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com. FORWARD-LOOKING DISCLAIMERThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.CONTACT INFORMATION: Investor Contact: ICR Scott Van Winkle 617-956-6736 scott.vanwinkle@icrinc.comMedia Contact: ICR Cory Ziskind 646-277-1232 cory.ziskind@icrinc.comA photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c785c75c-ef9a-4e2a-a7e8-8532e9f30b0e

  • CV Sciences, Inc. Announces Launch of CV™ Defense Daily Immune Support
    GlobeNewswire

    CV Sciences, Inc. Announces Launch of CV™ Defense Daily Immune Support

    CV™ Defense now available on CV Sciences website and launching on Amazon.com next week CV™ Defense CV™ Defense is a clinically supported immune formula that provides effective daily support for barrier immunity, innate immunity, and adaptive immunity.SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced its continued expansion into condition specific dietary supplements with the launch of CV™ Defense, the second of several products to be launched under its new Immunity product line, following the launch of CV™ Acute in August.  The expansion of CV Sciences’ non-CBD Immunity product line will continue to open markets and sales channels for the Company, including major e-commerce retailers not currently accessible by CBD-based products. CV™ Defense is now available on CV Sciences’ website (https://www.cvsciences.com/) and will be available next week on Amazon.com. Michael D. Lewis, MD, MPH, Colonel (Retired), U.S. Army, and CV Sciences Medical Advisor who participated in product development commented, “The fall and winter of 2020/2021 is shaping up to be one of the most challenging times that we have experienced in global public health. Now is the time to commit to fortifying the immune system with healthy lifestyle habits and science-backed supplementation provided by CV Sciences new immune products - CV™ Defense and CV™ Acute.”CV™ Defense is a clinically supported immune formula that provides effective daily support for barrier immunity, innate immunity, and adaptive immunity. CV Sciences’ team of doctors and scientists formulated this product with specific intent — to fortify daily immune health. Based on PEA (palmitoylethanolamide), a clinically researched ingredient to support the immune system, and combined with time-tested nutrients and botanicals, including vitamins A and D, the minerals selenium and zinc, and an Organic Reishi Mushroom Extract with concentrated β-glucans, CV™ Defense incorporates unique ingredients able to optimize immune response.In 1993, Nobel laureate Dr. Rita Levi-Montalcini discovered that PEA is used in the body to regulate certain immune cells in parallel with the endocannabinoid (ECS) system. These natural PEA levels can be supplemented by CV™ Defense through daily use. More than 3,000 participants took part in six double-blind, placebo-controlled clinical trials demonstrating that PEA has clear benefits for immune health. In addition to studies on immune health, multiple studies have demonstrated that PEA is safe and effective in supporting a balanced inflammatory response and improved gut barrier defense.“We evaluated hundreds of ingredients that would bring the strongest reinforcements to immune defense and make the most meaningful impact on health and wellness,” said Joseph Dowling, Chief Executive Officer of CV Sciences. “CV™ Defense is a unique formulation that is proven to provide daily immune support, which is critically important as we head into 2020/2021 flu season.”Dowling continued, “Our launch of CV™ Defense represents another key milestone in our strategic category expansion and continued evolution of CV Sciences’ positioning as a leading health and wellness company. We are pleased to make CV™ Defense broadly available and accessible to consumers through our website and Amazon.com, further supporting our ability to bring immunity health products to market. In addition, we believe that our CBD product line will be ideal companion products to our Immunity line since CBD supports the endocannabinoid system (ECS), and a healthy ECS supports immune health.” About CV Sciences, Inc.CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based dietary supplements and CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics. The Company’s PlusCBD™ products are sold at more than 6,300 retail locations throughout the U.S. and it is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry.  CV Sciences follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s products are processed, produced, and tested throughout the manufacturing process to confirm strict compliance with company standards and specifications.  With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov.  PlusCBD™ was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California.  Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com. FORWARD-LOOKING DISCLAIMERThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.CONTACT INFORMATION: Investor Contact: ICR Scott Van Winkle 617-956-6736 scott.vanwinkle@icrinc.comMedia Contact: ICR Cory Ziskind 646-277-1232 cory.ziskind@icrinc.comA photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/781695f4-a2dd-44f5-9a4f-72bdf1b0c172